Basic information
Biomarker: beta-catenin
Biomarker subtype: gene
Clinical application: diagnosis
Histology type: endometrial stromal tumor
Stage: low grade
Cohort characteristics
Country: Korea
Region: Seoul
Study type: retrospective study
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 31 | endometrial mesenchymal tumors | 2 | low-grade endometrial stromal sarcomas | 12 | undifferentiated endometrial sarcomas | 8 | uterine cellular leiomyomata | 9 |
Sample information
Sample type : tissue
Clinical method: Polymerase Chain Reaction
Expression pattern : exon 3
Disease information
Related information
Description: Taken together, these results indicate that nuclear beta-catenin immunostaining can serve as a sensitive immunohistochemical marker for the diagnosis of endometrial stromal tumors and is useful for differentiating low-grade endometrial stromal sarcomas from uterine cellular leiomyomata.
Expression figure legend: Box plot illustrating correlation between BMI-1 protein expression and mRNA BMI-1 expression.
Expression figure link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391115/figure/fig1/
